MBX Biosciences
Market cap $2.64B 49.7M shares (10-Q, Nov 5, 2026) × $53.10 close Nov 17, 2026
Most recent annual filing: 2026-03-12
- MBX 4291 Ph1 interim4Q 2026MBX 4291 Ph1 interim, 4Q 2026, material
- MBX 4291 Ph2 readout2027MBX 4291 Ph2 readout, 2027, notable
- Septerna SEP-479 readout1Q 2027Septerna SEP-479 readout, 1Q 2027, notable
- Amgen MariTide Ph3 readout2027Amgen MariTide Ph3 readout, 2027, notable
- MBX 5765 and 6180 trial2027MBX 5765 and 6180 trial, 2027, routine
- BridgeBio encaleret FDA decisionMay 8, 2027BridgeBio encaleret FDA decision, May 8, 2027, material
- Canvuparatide topline~About mid-2028 (estimate)Canvuparatide topline, ~About mid-2028 (estimate), thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
MBX 4291
MBX 5765
MBX 6180
Technology platforms
PEP
Precision Endocrine Peptide platform — proprietary peptide engineering and programmable prodrug technology combining multiple mechanisms of action, enhanced potency, improved stability and solubility, and fatty acylation for extended half-life; designed for once-monthly dosing with flattened, sustained exposure and improved tolerability; focus areas: endocrine and metabolic diseases including hypoparathyroidism and obesity
Targets: PTH, GLP-1 receptor, GIP receptor, GCGR, GLP-1, GIP, glucagon, DACRA, GCG, amylin receptor, calcitonin receptor, PTH1R
Discontinued (1)
- imapextide — Post-Bariatric Hypoglycemia · strategic deprioritization; capital reallocation to other pipeline programs
Capital (as filed)
- Cash
- $162M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $320M Sep 30, 2026
- Operating cash flow
- −$34.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $482M cash, runway into 2029 per the deep dive of Nov 13, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (1)
- 2026-11-16 MBX Biosciences (MBX) - Scientific Deep Dive for Canvuparatide, MBX 4291 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (1 call)
Every verdict Biotech Distilled has published on MBX Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-11-16 Watch MBX Biosciences (MBX) - Scientific Deep Dive for Canvuparatide, MBX 4291 and Pipeline Products At ~$2.4B EV the stock already prices a Phase 3 win; canvuparatide has not been shown to beat Yorvipath on anything but injection frequency, there is no issued U.S. patent, and the obesity leg has no interpretable data yet.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (2 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“We expect to present preclinical data from MBX 6180 at ObesityWeek in November 2026.”
matched to MBX 6180 · readout other
-
-
-
“12-week MAD (Part C) data for MBX 4291 on track for Q4 2026: Following initial Phase 1 data supporting the potential for once-monthly dosing, MBX remains on track to report unblinded data from the first cohort of the 12-week multiple ascending dose (MAD, Part C, Cohort 1) portion of its ongoing Phase 1 trial of MBX 4291.”
matched to MBX 4291 · interim data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (21)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. No press release captured yet; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 9, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- Nov 9, 202610-QQuarterly report
- Oct 22, 20268-KCurrent report: officer / director change
- Aug 27, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Aug 10, 2026SCHEDULE 13D/A13D amendment
- Aug 10, 2026SCHEDULE 13D/A13D amendment
- Aug 6, 20268-KCurrent report: results of operations, Reg FD disclosure, other events · EX-99.1
- Aug 6, 202610-QQuarterly report
- Jul 13, 20268-KCurrent report: officer / director change
- Jun 12, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Jun 5, 20268-KCurrent report: officer / director change, shareholder vote
- May 11, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- May 8, 2026DEFA14AProxy soliciting material
- May 7, 20268-KCurrent report: results of operations · EX-99.1
- May 7, 202610-QQuarterly report
- Apr 22, 2026DEFA14AProxy soliciting material
- Apr 22, 2026DEF 14AProxy statement
- Mar 12, 2026S-3ASRAutomatic shelf registration
- Mar 12, 20268-KCurrent report: results of operations · EX-99.1
- Mar 12, 202610-KAnnual report
- Mar 9, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
12 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 10, 2026S-8Employee plan registration
- Nov 5, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Jul 29, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 8, 2026SCHEDULE 13G/A13G amendment
- Jul 8, 2026SCHEDULE 13G/A13G amendment
- Jun 24, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 6, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 27, 2026SCHEDULE 13G/A13G amendment
- Apr 22, 2026ARSAnnual report to shareholders
- Mar 12, 2026S-8Employee plan registration